Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Short-term Investments (2016 - 2021)

Aptevo Therapeutics' Short-term Investments history spans 6 years, with the latest figure at $1.3 million for Q3 2021.

  • For Q3 2021, Short-term Investments fell 50.72% year-over-year to $1.3 million; the TTM value through Sep 2021 reached $1.3 million, down 50.72%, while the annual FY2020 figure was $2.6 million, N/A changed from the prior year.
  • Short-term Investments for Q3 2021 was $1.3 million at Aptevo Therapeutics, roughly flat from $1.3 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $73.7 million in Q4 2017 and bottomed at $400000.0 in Q3 2018.
  • The 5-year median for Short-term Investments is $7.4 million (2018), against an average of $18.0 million.
  • The largest annual shift saw Short-term Investments skyrocketed 64.3% in 2017 before it crashed 98.09% in 2018.
  • A 5-year view of Short-term Investments shows it stood at $73.7 million in 2017, then plummeted by 89.89% to $7.4 million in 2018, then increased by 0.67% to $7.5 million in 2019, then crashed by 65.92% to $2.6 million in 2020, then plummeted by 50.72% to $1.3 million in 2021.
  • Per Business Quant, the three most recent readings for APVO's Short-term Investments are $1.3 million (Q3 2021), $1.3 million (Q2 2021), and $1.3 million (Q1 2021).